Evidence Snapshot

Tubulin

CHEMBL2095182 PROTEIN COMPLEX GROUP Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T10:04:51Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 13, 2026, 7:04 PM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL2095182

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tubulin as ChEMBL target CHEMBL2095182, mapped to UniProt P68371. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Tubulin

PROTEIN COMPLEX GROUP · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL2095182

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P68371

Tubulin beta-4B chain

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Tubulin matters

As of 2026-09-13

Tubulin is reviewed as Tubulin beta-4B chain (UniProt P68371); Tubulin shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.; 40 linked drugs keep this evidence frame grounded.; the current evidence base includes 16 approved drugs, 2751 compounds, and 1499 assays, with lead potency reaching pChEMBL 10.3.

Protein context

Tubulin beta-4B chain

Tubulin beta-4B chain Sequence length is 445 aa.

Review this target as Tubulin, mapped to UniProt P68371. ChEMBL maps the protein component as Tubulin beta-4B chain. Sequence length is 445 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P68371 Protein

Disease context

neoplasm

Tubulin shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 40 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ANETUMAB RAVTANSINE, ANG1005, ANVATABART OPADOTIN.

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include ANETUMAB RAVTANSINE, ANG1005, ANVATABART OPADOTIN, BELANTAMAB MAFODOTIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 40 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 16 approved drugs, 2751 compounds, and 1499 assays for this target. The dominant activity type is IC50. CHEMBL5194719 is the current potency anchor at pChEMBL 10.3.

Use CHEMBL5194719 as the tractability anchor when discussing potency (pChEMBL 10.3).

Activity source · ChEMBL 36 via Core Engine

16 approved pChEMBL 10.3

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Tubulin matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P68371, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why neoplasm is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2751

Total Compounds

1499

Total Assays

Approved Drugs

IC50: 1491.0, KI: 25.0, EC50: 70.0, KD: 83.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL5194719	10.3	IC50	—
No preferred name CHEMBL5203711	9.8	IC50	—
No preferred name CHEMBL553025	9.5	IC50	Approved
No preferred name CHEMBL39541	9.3	IC50	Clinical
No preferred name CHEMBL5169466	8.9	IC50	—